Plexopathy after COVID-19 Vaccination

 The lymphatic system in our body acts as a sewage system, filtering out waste and helping fight infections. Axillary lymphadenopathy is a condition where the lymph nodes (small, bean-shaped structures in the lymphatic system) located in the armpit (axilla) area swell up. This usually happens when the body is trying to fight off an infection or in response to certain medications or vaccines.

The brachial plexus is a network of nerves that send signals from your spinal cord to your shoulder, arm, and hand. A plexopathy is a disorder that affects this network of nerves, leading to various symptoms including pain, numbness, and muscle weakness in the affected area. 

Multiple case reports described lymphadenopathy after COVID-19 vaccination. Previously we talked about vaccine-triggered Parsonage-Turner syndrome, a rare idiopathic brachial plexopathy in a 50-year old male. 34-year-old healthy male also developed brachial plexus neuropraxia (a mild nerve injury) after getting the Covid vaccine. First, he exhibited unilateral axillary lymphadenopathy after receiving an mRNA COVID-19 vaccine that led to his swollen lymph nodes causing pressure on the brachial plexus, leading to medial cord plexopathy. This presented as nerve pain, a pins-and-needles sensation (paresthesia), and numbness in the patient's hand. Another case of unilateral lymphadenopathy resulting in a transient plexopathy presenting as neuralgic pain, paresthesia, and numbness in the hand, was published in JBJS Case Connect.

Diagnostic imaging and electrodiagnostic studies help to identify the condition. Similar cases were reported, such as a 52-year-old man with hypertension and diabetes who developed severe brachial plexopathy following a battle with COVID-19.


REFERENCES

Sharma A, Gupta A. A rare case of brachial plexus neuropraxia after COVID-19 vaccination. Cureus. 2022 Jan 14;14(1).

Wu J, Oitment C, Silverman J, Grey TM, Bhanot K. Unilateral Axillary Lymphadenopathy After COVID-19 Vaccine Causing Medial Cord Plexopathy: A Case Report. JBJS Case Connect. 2022 Jun 22;12(2). doi: 10.2106/JBJS.CC.21.00712. PMID: 37440670.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

Navigating the Tripledemic: JN.1, RSV, and Flu Update

Image
The respiratory viruses are out there.  Wastewater viral activity levels for COVID-19 , as reported by the Centers for Disease Control and Prevention, have reached the highest point since the Omicron surge in 2022. The levels are also high in Canada . The three primary respiratory illnesses continue to circulate at very high levels. But despite the triple threat of  SARS-Cov-2, respiratory syncytial virus ( RSV ) and the flu , there is a notable lack of community attention.   JN.1 (Pirola,  BA.2.86 ,  with additional L455S mutation, descending from a  de-escalated  variant of concern BA.2), initially detected on August 25 2023, has evolved from a variant under monitoring to a  variant of interest. Variants like Acrux (XBB.2.3, that began to spread worldwide soon after WHO declared the end of the pandemic) are  no longer relevant , but a few now less prevalent variants such as  Centaurus  (BA.2.75) and XBB, a hybrid of Centaurus with BA.2 lineage, that  gave rise to  Eris , its descend
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more